Cargando…
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
BACKGROUND & AIMS: We created and validated a clinical decision support tool (CDST) to predict outcomes of vedolizumab therapy for ulcerative colitis (UC). METHODS: We performed logistic regression analyses of data from the GEMINI 1 trial, from 620 patients with UC who received vedolizumab induc...
Autores principales: | Dulai, Parambir S., Singh, Siddharth, Casteele, Niels Vande, Meserve, Joseph, Winters, Adam, Chablaney, Shreya, Aniwan, Satimai, Shashi, Preeti, Kochhar, Gursimran, Weiss, Aaron, Koliani-Pace, Jenna L., Gao, Youran, Boland, Brigid S., Chang, John T., Faleck, David, Hirten, Robert, Ungaro, Ryan, Lukin, Dana, Sultan, Keith, Hudesman, David, Chang, Shannon, Bohm, Matthew, Varma, Sashidhar, Fischer, Monika, Shmidt, Eugenia, Swaminath, Arun, Gupta, Nitin, Rosario, Maria, Jairath, Vipul, Guizzetti, Leonardo, Feagan, Brian G., Siegel, Corey A., Shen, Bo, Kane, Sunanda, Loftus, Edward V., Sandborn, William J., Sands, Bruce E., Colombel, Jean-Frederic, Lasch, Karen, Cao, Charlie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899124/ https://www.ncbi.nlm.nih.gov/pubmed/32062041 http://dx.doi.org/10.1016/j.cgh.2020.02.010 |
Ejemplares similares
-
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes
por: Koliani-Pace, Jenna L, et al.
Publicado: (2019) -
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
por: Lukin, Dana, et al.
Publicado: (2020) -
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis
por: Faleck, David M., et al.
Publicado: (2019) -
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
por: Narula, Neeraj, et al.
Publicado: (2019) -
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)